Functional Characterization of BRCA1 Gene Variants by Mini-gene Splicing Assay

Overview

Journal Eur J Hum Genet

Specialty Genetics

Date 2014 Mar 27

PMID 24667779

Citations 42

Authors

Ane Y Steffensen

Mette Dandanell

Lars Jonson

Bent Ejlertsen

Anne-Marie Gerdes

Finn C Nielsen

Thomas vO Hansen

Affiliations

Soon will be listed here.

Abstract

Mutational screening of the breast cancer susceptibility gene BRCA1 leads to the identification of numerous pathogenic variants such as frameshift and nonsense variants, as well as large genomic rearrangements. The screening moreover identifies a large number of variants, for example, missense, silent, and intron variants, which are classified as variants of unknown clinical significance owing to the lack of causal evidence. Variants of unknown clinical significance can potentially have an impact on splicing and therefore functional examinations are warranted to classify whether these variants are pathogenic or benign. Here we validate a mini-gene splicing assay by comparing the results of 24 variants with previously published data from RT-PCR analysis on RNA from blood samples/lymphoblastoid cell lines. The analysis showed an overall concordance of 100%. In addition, we investigated 13 BRCA1 variants of unknown clinical significance or putative variants affecting splicing by in silico analysis and mini-gene splicing assay. Both the in silico analysis and mini-gene splicing assay classified six BRCA1 variants as pathogenic (c.80+1G>A, c.132C>T (p.=), c.213-1G>A, c.670+1delG, c.4185+1G>A, and c.5075-1G>C), whereas six BRCA1 variants were classified as neutral (c.-19-22_-19-21dupAT, c.302-15C>G, c.547+14delG, c.4676-20A>G, c.4987-21G>T, and c.5278-14C>G) and one BRCA1 variant remained unclassified (c.670+16G>A). In conclusion, our study emphasizes that in silico analysis and mini-gene splicing assays are important for the classification of variants, especially if no RNA is available from the patient. This knowledge is crucial for proper genetic counseling of patients and their family members.

Citing Articles

Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics.

Witz A, Dardare J, Betz M, Michel C, Husson M, Gilson P Biomark Res. 2025; 13(1):31.

PMID: 39985088 PMC: 11846297. DOI: 10.1186/s40364-025-00740-y.

Identified eleven exon variants in PKD1 and PKD2 genes that altered RNA splicing by minigene assay.

Liu X, Shi X, Xin Q, Liu Z, Pan F, Qiao D BMC Genomics. 2023; 24(1):407.

PMID: 37468838 PMC: 10354997. DOI: 10.1186/s12864-023-09444-9.

Case report: Functional characterization of a novel intronic variant in patients with CHARGE syndrome.

Rossi C, Ramadan S, Evangelisti C, Ferrari S, Accadia M, Toydemir R Front Genet. 2023; 14:1082100.

PMID: 36845402 PMC: 9947648. DOI: 10.3389/fgene.2023.1082100.

SPiP: Splicing Prediction Pipeline, a machine learning tool for massive detection of exonic and intronic variant effects on mRNA splicing.

Leman R, Parfait B, Vidaud D, Girodon E, Pacot L, Le Gac G Hum Mutat. 2022; 43(12):2308-2323.

PMID: 36273432 PMC: 10946553. DOI: 10.1002/humu.24491.

Targeted Next-Generation Sequencing of Congenital Hypothyroidism-Causative Genes Reveals Unexpected Thyroglobulin Gene Variants in Patients with Iodide Transport Defect.

Bernal Barquero C, Geysels R, Jacques V, Carro G, Martin M, Peyret V Int J Mol Sci. 2022; 23(16).

PMID: 36012511 PMC: 9409291. DOI: 10.3390/ijms23169251.

References

Claes K, Vandesompele J, Poppe B, Dahan K, Coene I, De Paepe A . Pathological splice mutations outside the invariant AG/GT splice sites of BRCA1 exon 5 increase alternative transcript levels in the 5' end of the BRCA1 gene. Oncogene. 2002; 21(26):4171-5. DOI: 10.1038/sj.onc.1205520. View

Claes K, Poppe B, Machackova E, Coene I, Foretova L, De Paepe A . Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2. Genes Chromosomes Cancer. 2003; 37(3):314-20. DOI: 10.1002/gcc.10221. View

Beristain E, Martinez-Bouzas C, Guerra I, Viguera N, Moreno J, Ibanez E . Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling. Breast Cancer Res Treat. 2007; 106(2):255-62. DOI: 10.1007/s10549-006-9489-0. View

Fetzer S, Tworek H, Piver M, DiCioccio R . Classification of IVS1-10T-->C as a polymorphism of BRCA1. Cancer Genet Cytogenet. 1999; 113(1):58-64. DOI: 10.1016/s0165-4608(99)00005-9. View

Spurdle A, Couch F, Hogervorst F, Radice P, Sinilnikova O . Prediction and assessment of splicing alterations: implications for clinical testing. Hum Mutat. 2008; 29(11):1304-13. PMC: 2832470. DOI: 10.1002/humu.20901. View

Hansen T, Jonson L, Albrechtsen A, Andersen M, Ejlertsen B, Nielsen F . Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families. Breast Cancer Res Treat. 2008; 115(2):315-23. DOI: 10.1007/s10549-008-0088-0. View

Church D, Stotler C, Rutter J, Murrell J, Trofatter J, Buckler A . Isolation of genes from complex sources of mammalian genomic DNA using exon amplification. Nat Genet. 1994; 6(1):98-105. DOI: 10.1038/ng0194-98. View

van der Kolk D, de Bock G, Leegte B, Schaapveld M, Mourits M, De Vries J . Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat. 2010; 124(3):643-51. DOI: 10.1007/s10549-010-0805-3. View

Tammaro C, Raponi M, Wilson D, Baralle D . BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer. Biochem Soc Trans. 2012; 40(4):768-72. DOI: 10.1042/BST20120140. View

10.

King M, Marks J, Mandell J . Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302(5645):643-6. DOI: 10.1126/science.1088759. View

11.

Antoniou A, Pharoah P, Narod S, Risch H, Eyfjord J, Hopper J . Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72(5):1117-30. PMC: 1180265. DOI: 10.1086/375033. View

12.

Sanz D, Acedo A, Infante M, Duran M, Perez-Cabornero L, Esteban-Cardenosa E . A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. Clin Cancer Res. 2010; 16(6):1957-67. DOI: 10.1158/1078-0432.CCR-09-2564. View

13.

Houdayer C, Caux-Moncoutier V, Krieger S, Barrois M, Bonnet F, Bourdon V . Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat. 2012; 33(8):1228-38. DOI: 10.1002/humu.22101. View

14.

Walker L, Whiley P, Houdayer C, Hansen T, Vega A, Santamarina M . Evaluation of a 5-tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data: inter-reviewer variability and promotion of minimum reporting guidelines. Hum Mutat. 2013; 34(10):1424-31. DOI: 10.1002/humu.22388. View

15.

Colombo M, De Vecchi G, Caleca L, Foglia C, Ripamonti C, Ficarazzi F . Comparative in vitro and in silico analyses of variants in splicing regions of BRCA1 and BRCA2 genes and characterization of novel pathogenic mutations. PLoS One. 2013; 8(2):e57173. PMC: 3579815. DOI: 10.1371/journal.pone.0057173. View

16.

Bonnet C, Krieger S, Vezain M, Rousselin A, Tournier I, Martins A . Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet. 2008; 45(7):438-46. DOI: 10.1136/jmg.2007.056895. View

17.

Machackova E, Foretova L, Lukesova M, Vasickova P, Navratilova M, Coene I . Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. BMC Cancer. 2008; 8:140. PMC: 2413254. DOI: 10.1186/1471-2407-8-140. View

18.

Baralle D, Lucassen A, Buratti E . Missed threads. The impact of pre-mRNA splicing defects on clinical practice. EMBO Rep. 2009; 10(8):810-6. PMC: 2726684. DOI: 10.1038/embor.2009.170. View

19.

Thery J, Krieger S, Gaildrat P, Revillion F, Buisine M, Killian A . Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes. Eur J Hum Genet. 2011; 19(10):1052-8. PMC: 3190263. DOI: 10.1038/ejhg.2011.100. View

20.

Hansen T, Bisgaard M, Jonson L, Albrechtsen A, Filtenborg-Barnkob B, Eiberg H . Novel de novo BRCA2 mutation in a patient with a family history of breast cancer. BMC Med Genet. 2008; 9:58. PMC: 2478678. DOI: 10.1186/1471-2350-9-58. View